Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Amigo Jiménez, Irene ^a   Bailón, Elvira ^a   Ugarte Berzal, Estefanía ^a   Aguilera Montilla, Noemí ^a   García Marco, José A ^b   García Pardo, Angeles ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; FLUDARABINE; GELATINASE B; HERMES ANTIGEN; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; VERY LATE ACTIVATION ANTIGEN 4; MCL1 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN MCL 1; VIDARABINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL MIGRATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; CELL MEMBRANE; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD44; APOPTOSIS; ARSENICALS; CELL MEMBRANE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEK293 CELLS; HUMANS; INTEGRIN ALPHA4BETA1; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION, GENETIC; UP-REGULATION; VIDARABINE;

EID: 84903532650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099993     Document Type: Article

References (41)

1. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10: 37-50.
2. Gaidano G, Foa, Dalla-Favera R (2012) Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 122: 3432-3438.
3. Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6: 405-418.
4. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88: 803-816.
5. Stephens DM, Byrd JC (2013) Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. Hematol Oncol Clin North Am 27: 303-327.
6. Wang Z-Y, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
7. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z (2012) How to manage acute promyelocytic leukemia. Leukemia 26: 1743-1751.
8. Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, et al. (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86: 541-552.
9. Redondo-Muñoz J, Escobar-Díaz E, Hernández del Cerro M, Pandiella A, Terol MJ, et al. (2010) Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 16: 4382-4391.
10. Burger JA (2012) Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24: 643-649.
11. Ramsay AD, Rodriguez-Justo M (2013) Chronic lymphocytic leukemia-the role of the microenvironment pathogenesis and therapy. Br J Haematol 162: 15-24.
12. Vandooren J, Van den Steen PE, Opdenakker G (2013) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48: 222-272.
13. Bauvois B, Dumont J, Mathiot C, Kolb JP (2002) Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 16: 791-798. (Pubitemid 34537550)
14. Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, et al. (2006) MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108: 3143-3151.
15. Redondo-Muñoz J, Terol MJ, García-Marco JA, García-Pardo A (2008) Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 111: 383-386.
16. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, Hernández del Cerro M, Van den Steen PE, et al. (2008) a4b1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169-178.
17. Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández del Cerro M, et al. (2010) Matrix Metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through Its hemopexin domain. Cancer Cell 17: 160-172.
18. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2: 161-174. (Pubitemid 37328786)
19. Mannello F, Luchetti E, Falcieri E, Papa S (2005) Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10: 19-24. (Pubitemid 40558112)
20. Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, Van den Steen P, Opdenakker G, et al. (2014) Overexpression of pro-gelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. J Leuk Biol, in press.
21. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P (1999) MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23: 127-136. (Pubitemid 29067556)
22. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H (1992) Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285: 603-611.
23. Shooshtari P, Fortuno ES, Blimkie D, Yu M, Gupta A, et al. (2010) Correlation Analysis of Intracellular and Secreted Cytokines via the Generalized Integrated Mean Fluorescence Intensity (GiMFI). Cytometry A 77: 873-880.
24. Jayo A, Conde I, Lastres P, Martínez C, Rivera J, et al. (2010) L718P mutation in the membrane-proximal cytoplasmic tail of b3 promotes abnormal aIIb3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica 95: 1158-1166.
25. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37: 375-536. (Pubitemid 36071972)
26. Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71-81.
27. Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49-63.
28. Gandhi V, Balakrishnan K, Chen LS (2008) Mcl-1: the 1 in CLL. Blood 112: 3538-3540.
29. Nyormoi O, Mills L, Bar-Eli M (2003) An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10: 558-569. (Pubitemid 36656645)
30. Meyer E, Vollmer JY, Boyer R, Stamenkovic (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 65: 4261-4272. (Pubitemid 40775665)
31. Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK (2010) Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther 9: 2605-2617.
32. Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R (2011) Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Research 71: 6986-6996.
33. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, et al. (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5: 3113-3121. (Pubitemid 46092053)
34. Balakrishnan K, Burger JA, Wierda WG, Gandhi V (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113: 149-153.
35. Buchner M, Baer C, Prinz G, Dierks C, Burger M, et al. (2010) Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115: 4497-4506.
36. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M (2008) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112: 2450-2460.
37. Wang R, Xia L, Gabrilove J, Waxman S, Jing Y (2013) Downregulation of Mcl-1 through GSK-3b activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 27: 315-324.
38. Baysan A (2007) Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 30: 313-318.
39. Morales AA, Gutman D, Boise LH (2008) BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111: 5152-5162.
40. Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, et al. (2013) BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis 4: e628.
41. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, et al. (2002) Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71: 495-502.